Amrize Ltd carries a market capitalization of 22.43B, placing it among publicly traded companies globally. Its enterprise value stands at 35.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 22.43B |
| Enterprise Value | 35.72B |
Amrize Ltd currently has 549.78M shares outstanding.
| Shares Outstanding | 549.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Amrize Ltd trades at a trailing price-to-earnings ratio of 24.46. The price-to-sales ratio is 2.42, and the price-to-book ratio stands at 2.28.
| PE Ratio | 24.46 |
| PS Ratio | 2.42 |
| PB Ratio | 2.28 |
| P/TBV Ratio | 13.69 |
| P/FCF Ratio | 9.72 |
| P/OCF Ratio | 13.56 |
On an enterprise value basis, Amrize Ltd trades at an EV/EBITDA multiple of 12.60 and an EV/FCF ratio of 10.86. The EV/Sales ratio of 2.93 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.95 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.93 |
| EV / EBITDA | 12.60 |
| EV / EBIT | 18.95 |
| EV / FCF | 10.86 |
Amrize Ltd maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.63, indicating elevated leverage, while an interest coverage ratio of 8.51 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.10 |
| Quick Ratio | 0.67 |
| Debt / Equity | 55.63 |
| Debt / EBITDA | 2.52 |
| Interest Coverage | 8.51 |
Amrize Ltd posts a return on equity of 9.53 and a return on invested capital of 7.25.
| Return on Equity (ROE) | 9.53 |
| Return on Assets (ROA) | 4.98 |
| Return on Invested Capital (ROIC) | 7.25 |
| Return on Capital Employed (ROCE) | 7.40 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.72 |
Over the trailing twelve months, Amrize Ltd has paid 369.00M in income taxes, reflecting an effective tax rate of 23.70.
| Income Tax | 369.00M |
| Effective Tax Rate | 23.70 |
Amrize Ltd's stock has declined approximately -26.40756% over the past 52 weeks. The 50-day moving average sits at 47.40, while the 200-day moving average is 53.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.40756% |
| 50-Day Moving Average | 47.40 |
| 200-Day Moving Average | 53.39 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Amrize Ltd generated 12.19B in revenue and converted that into 1.21B in net income, yielding earnings per share of 2.17. EBITDA reached 2.84B, while operating income came in at 1.89B.
| Revenue | 12.19B |
| Gross Profit | 3.05B |
| Operating Income | 1.89B |
| Pretax Income | 1.56B |
| Net Income | 1.21B |
| EBITDA | 2.84B |
| EBIT | 1.89B |
| Earnings Per Share (EPS) | 2.17 |
Amrize Ltd holds 729.00M in cash and equivalents against 7.15B in total debt, resulting in a net debt position of 5.28B. Total book value stands at 12.87B, with working capital of 430.00M providing operational flexibility.
| Cash & Cash Equivalents | 729.00M |
| Total Debt | 7.15B |
| Net Debt | 5.28B |
| Equity (Book Value) | 12.87B |
| Book Value Per Share | 23.40 |
| Working Capital | 430.00M |
Amrize Ltd produced 2.17B in operating cash flow over the past twelve months. After subtracting -860.00M in capital expenditures, free cash flow totaled 1.31B - equivalent to 2.38 per share.
| Operating Cash Flow | 2.17B |
| Capital Expenditures | -860.00M |
| Free Cash Flow | 1.31B |
| FCF Per Share | 2.38 |
Amrize Ltd operates with a gross margin of 25.03, reflecting its pricing power and cost economics. The operating margin of 15.47 and net profit margin of 9.89 provide insight into operational efficiency.
| Gross Margin | 25.03 |
| Operating Margin | 15.47 |
| Pretax Margin | 12.78 |
| Profit Margin | 9.89 |
| EBITDA Margin | 23.26 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 2.73 |
| FCF Yield | 10.28 |
Amrize Ltd posts an Altman Z-Score of 2.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.96 |